首页> 外文期刊>International journal of antimicrobial agents >Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002
【24h】

Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002

机译:确定来自17个国家/地区的38个中心的产广谱β-内酰胺酶的肠杆菌科细菌,耐万古霉素的粪便肠球菌和耐甲氧西林的金黄色葡萄球菌的发生率:PEARLS研究2001-2002

获取原文
获取原文并翻译 | 示例
           

摘要

The PEARLS study prospectively monitored selected nosocomial pathogens from 38 centres in 13 European, three Middle Eastern countries and South Africa during 2001-2002. Extended spectrum P-lactamase (ESBL) production rates among Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp. were 5.4% (142/2609), 18.2% (401/2206) and 8.8% (204/2328), respectively, for all study sites. The overall ESBL production rate for the combined Enterobacteriaceae was 10.5% (747/7143), highest in Egypt, 38.5%, and Greece, 27.4%, and lowest in The Netherlands, 2.0%, and Germany, 2.6%. JEF, PCR and DNA sequencing determined 10.7% false positives among Enterobacter spp. when using NCCLS guidelines to screen for ESBL production. The prevalence of nosocomial methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium was 32.4% (294/908) and 8.7% (83/949), respectively. PEARLS provides baseline data against which prospective changes in resistant determinants and outcomes can be measured in this ongoing study. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
机译:PEARLS研究在2001-2002年期间对来自13个欧洲,三个中东国家和南非的38个中心的选定医院病原体进行了前瞻性监测。大肠埃希氏菌,肺炎克雷伯菌和肠杆菌属细菌中的超广谱P-内酰胺酶(ESBL)生产率。在所有研究地点,分别为5.4%(142/2609),18.2%(401/2206)和8.8%(204/2328)。合并肠杆菌科的总ESBL生产率为10.5%(747/7143),埃及最高,为38.5%,希腊为27.4%,荷兰最低,为2.0%,德国最低,为2.6%。 JEF,PCR和DNA测序确定了肠杆菌属细菌中10.7%的假阳性。使用NCCLS指南筛选ESBL产品时。医院内耐甲氧西林的金黄色葡萄球菌和耐万古霉素的粪肠球菌的患病率分别为32.4%(294/908)和8.7%(83/949)。 PEARLS提供了基线数据,在此正在进行的研究中,可以根据这些基线数据测量耐药性决定因素和结果的前瞻性变化。 (C)2004年Elsevier B.V.和国际化学疗法学会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号